FSII, FSI International, Inc.
** On its second quarter fiscal 2012, FSII posted sales of $38.5 million, a 25% increase year over year, while orders grew 123% to $51.4 million, compared to the prior year period, as FSII?s ORION(R) and ANTARES(R) systems gain broader market adoption.
FSII is a global supplier of surface conditioning equipment, technology and support services for microelectronics manufacturing. Using FSII?s broad portfolio of cleaning products, which include batch and single-wafer platforms for immersion, spray and cryogenic aerosol technologies, customers are able to achieve their process performance flexibility and productivity goals.
More about FSII at www.fsi-intl.com
AMRN, Amarin Corporation plc
** AMRN reported that the U.S. Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for U.S. Patent Application Serial Number 12/052,598 titled "Highly Purified Ethyl EPA and Other EPA Derivatives," also known as the EPA with no DHA in a capsule application.
A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application.
AMR101 (icosapent ethyl) is an ultra pure omega-3 fatty acid, comprising not less than 96% EPA (icosapent ethyl), that AMRN is developing as a treatment for patients with very high triglyceride levels (>=500 mg/dL), and for patients with high triglyceride levels (>=200 and <500mg/dL) who are also on statin therapy for elevated low-density lipoprotein cholesterol, or LDL-C, levels.
The efficacy and safety of AMR101 were studied in two Phase 3 clinical trials, the MARINE trial, which studied patients with very high triglyceride levels, and the ANCHOR trial, which studied patients with high triglyceride levels who were also on statin therapy for elevated LDL-C levels. These two Phase 3 clinical trials showed favorable results in triglyceride reduction compared to placebo in the studied patient populations. Reduction in triglyceride levels was achieved without a statistically significant increase in LDL-C levels, and in the 4 gram AMR101 ANCHOR results, with a statistically significant decrease in LDL-C levels.
AMRN is a late-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease.
AMRN has filed a New Drug Application (NDA) with the FDA for the use of its lead product candidate, AMR101, in the treatment of patients with very high triglyceride levels (the population studied in AMRN's MARINE trial), and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 26, 2012 for the completion of its review.
AMRN plans to separately seek approval for use of AMR101 in the treatment of patients with high triglyceride levels who are also on statin therapy for elevated LDL-C levels, the population studied in the ANCHOR trial, if the FDA approves the MARINE indication and after the REDUCE-IT cardiovascular outcomes trial is substantially underway.
More about AMRN at www.amarincorp.com
WSCI, WSI Industries Inc.
** For its fiscal 2012 second quarter, WSCI posted sales of $7,021,000, a 24% increase year over year, and net income of $171,000 or $.06 per diluted share, a 45% increase compared to the same period the prior year.
WSCI reported that it has signed a five year agreement with an existing aerospace customer to continue to provide them parts.
WSCI is a leading contract manufacturer that specializes in the machining of complex, high-precision parts for a wide range of industries, including avionics and aerospace, energy, recreational vehicles, small engines, marine, bioscience and the defense markets.
More about WSCI at www.wsci.com
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.